Zynex, Inc. (ZYXI) Tops Q1 EPS by 1c, Revenues Beat; Offers 2Q & FY21 Revenues Mid-Point Guidance Above Consensus

Zynex, Inc. (NASDAQ: ZYXI) reported Q1 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $24.1 million versus the consensus estimate of $23.67 million.

2021 First Quarter

Revenue increased 58% year over year to $24.1 million
Orders increased 140%
Net loss of $0.7 million; GAAP loss per share $0.02
Adjusted EBITDA loss $0.4 million

President and CEO Commentary:Thomas Sandgaard, CEO said: "I am excited about our order growth in the first quarter of 140% which will continue to drive increasing revenue throughout 2021 and 2022. In the first quarter, we posted revenue of $24.1 million. First quarter revenue is historically affected by health insurance deductibles not being met in the beginning of the year. The combination of seasonality of deductibles along with the sales force investments we made during 2020 produced a small loss in Q1 which was expected. Profitability is expected to ramp quickly beginning in second quarter with projected Adjusted EBITDA of over $3 million.

In the first quarter, we focused on productivity of our existing sales reps and trimmed our sales force slightly below 500. We still expect to have over 600 sales reps by the end of 2021 with most of those additions coming in the second half of the year.

We continue to advocate for pain patients, and for physicians to prescribe our NexWave technology as the first line of defense in treating chronic and acute pain without side effects. We are dedicated to promoting our technology in an effort to remove patient addiction and other side effects from prescription opioids."

GUIDANCE:

Zynex, Inc. sees Q2 2021 revenue of $31-32.5 million, versus the consensus of $31.43 million.

Zynex, Inc. sees FY2021 revenue of $135-150 million, versus the consensus of $138.59 million.

Second Quarter and Full Year 2021 Guidance:The estimated range for second quarter revenue is between $31.0 and $32.5 million with Adjusted EBITDA between $3.0 and $4.0 million. The revenue estimate is approximately 61% to 69% above 2020 second quarter revenue of $19.3 million.

Full year 2021 revenue is estimated between $135.0 and $150.0 million with Adjusted EBITDA between $15.0 and $25.0 million. The full year revenue estimate is approximately 68% to 87% above 2020 revenue of $80.1 million. We expect profitability to continually ramp throughout the year to meet our Adjusted EBITDA forecast of $15 to $25 million for 2021.

For earnings history and earnings-related data on Zynex, Inc. (ZYXI) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Central Securities (CET) Releases Report to Stockholders
• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition